![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC ACQUIRES ONCOLOGY PRODUCT CANDIDATES
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC ACQUIRES ONCOLOGY PRODUCT CANDIDATES
November 2, 2005
Cambridge Antibody Technology is buying two experimental cancer drugs from a unit of Denmark's Danisco for up to $16 million to boost its drugs pipeline, the UK biotech firm said on Tuesday. CAT said it was buying GCR-3888, which is in intermediate Phase II clinical trials for hairy cell leukemia (HCL), and GCR-8015, a preclinical treatment for cancers including non-Hodgkin's lymphoma, from Danisco's Genencor unit.
ABC News (http://abcnews.go.com/Health/wireStory?id=1269632)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct